SAREPTA THERAPEUTICS INC

SRPTNASDAQ

🏆 #1584 by market capEarnings Nov 4US Equity

$18.22▲ $1.10 (+6.05%)

Live

1h—

24h▲ 6.0%

7d▲ 14.4%

14d▲ 17.3%

30d▼ 3.2%

1y▼ 3.1%

🏦Market Cap

$1.92B

Small Cap

📈Revenue Growth (YoY)

-20.4%

Declining

📊Gross Margin

67.5%

High

💵FCF Margin

16.4%

Healthy

⚖️P/S Ratio

0.9x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $18.14 – $18.58
52-Week Range: $14.68 – $25.32
Volume: $3.96B
Avg Volume: $4.72B
Shares Outstanding: 105.6M
Next Earnings: Oct 27, 2026

Fundamentals Snapshot

Annual Revenue: $2.20B
Last Q Revenue: $401M
P/E Ratio: —
P/S Ratio: 0.9x
EPS (TTM): $-1.82
Dividend Yield: —

Why Investors Own SRPT

✓High-growth profile — revenue up -1.9% YoY with expanding US Equity exposure.
✓Healthy economics — 74% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2.20B▼ −6.4% YoY

Gross Margin (TTM)

74.3%▲ +1.9% YoY

Operating Income (TTM)

$473M▼ −6.4% YoY

Free Cash Flow (TTM)

$431M▼ −6.4% YoY

About SAREPTA THERAPEUTICS INC

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

🦦